Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) filed its monthly return for the period ended 31 May 2026, detailing steady capital structure and an active share repurchase programme.

Key takeaways

1. Share buy-backs • 405,800 H-shares were repurchased during the month through on-market transactions authorised on 12 February 2026. • Estimated consideration totalled HKD 12.08 million, implying an average price of HKD 29.78 per share. • The buy-backs reduced the number of shares in public hands by 0.30 percentage points, lowering issued shares (excluding treasury stock) to 135.35 million.

2. Treasury share position • All repurchased shares were retained as treasury stock, increasing the treasury balance to 866,000 shares—about 0.64 % of the 136.22 million total issued shares. • No shares were cancelled during the month.

3. Share capital stability • Authorised/issued share capital remained unchanged at 136.22 million H-shares with a par value of RMB 0.1, equivalent to RMB 13.62 million. • The company did not issue any new shares, warrants, options or convertible securities.

4. Compliance with listing rules • HANXBIO-B confirmed that its public float continues to meet the Main Board’s 25 % minimum requirement as of 31 May 2026. • All repurchases were executed in accordance with the board’s mandate and relevant regulatory provisions.

The monthly update signals HANXBIO-B’s continued use of share repurchases to manage capital while preserving regulatory compliance and maintaining a stable share base.